NEW YORK (GenomeWeb) – Quidel announced after the close of market on Monday that it expects its fourth quarter revenues to be in the range of $132 million to $133 million, which would be up 15 to 16 percent from a year ago.

In Q4 2017, the San Diego-based maker of rapid diagnostic testing solutions and molecular diagnostic systems reported revenues of $114.9 million.

The preliminary results would be even with the consensus Wall Street estimate of $132.1 million.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.